Chaim Indig - Phreesia Chief Executive Officer, Board Member
| PHR Stock | USD 21.10 0.07 0.33% |
CEO
Mr. Chaim Indig is Chief Executive Officer and Board Member of Phreesia, Inc. Since cofounding Phreesia in 2005, Chaim Indig has helped revolutionize the patient intake experience. Under his leadership, Phreesia has established a broad national footprint, developed strategic partnerships with some of the worlds largest healthcare companies, and earned accolades for its role in making healthcare more efficient and patientcentered. Prior to founding Phreesia, he held key roles at Spotfire and OLAPWork. Chaim is also a recognized business leader, trusted industry expert and soughtafter speaker. He was a finalist for Ernst Youngs Entrepreneur of the Year Award and was featured in the Stanford Social Innovation Review as a healthcare innovator. since 2005.
| Age | 44 |
| Tenure | 19 years |
| Address | 1521 Concord Pike, Wilmington, DE, United States, 19803 |
| Phone | 888 654 7473 |
| Web | https://www.phreesia.com |
Latest Insider Transactions
Phreesia Management Efficiency
The company has Return on Asset of (0.1664) % which means that on every $100 spent on assets, it lost $0.1664. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.4026) %, meaning that it generated no profit with money invested by stockholders. Phreesia's management efficiency ratios could be used to measure how well Phreesia manages its routine affairs as well as how well it operates its assets and liabilities. As of 12/02/2024, Return On Tangible Assets is likely to drop to -0.66. In addition to that, Return On Capital Employed is likely to drop to -0.53. At this time, Phreesia's Net Tangible Assets are relatively stable compared to the past year. As of 12/02/2024, Non Current Assets Total is likely to grow to about 183.4 M, while Non Currrent Assets Other are likely to drop slightly above 3.3 M.Similar Executives
| Found 5 records | CEO Age | ||
| Michael Hays | National Research Corp | 69 | |
| Dan McCarthy | Evolent Health | 39 | |
| Kevin Coop | Definitive Healthcare Corp | 59 | |
| Seth Blackley | Evolent Health | 45 | |
| Parth Mehrotra | Privia Health Group | 45 | |
Management Performance
| Return On Equity | -0.4 | ||||
| Return On Asset | -0.17 |
Phreesia Leadership Team
Elected by the shareholders, the Phreesia's board of directors comprises two types of representatives: Phreesia inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Phreesia. The board's role is to monitor Phreesia's management team and ensure that shareholders' interests are well served. Phreesia's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Phreesia's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Davidoff, Senior Vice President - Marketing and Business Development | ||
| Evan Roberts, Co-Founder, Vice President - Customer Solutions | ||
| Scott Perricelli, Independent Director | ||
| Charles Kallenbach, General Counsel, Secretary | ||
| Chaim Indig, Chief Executive Officer, Board Member | ||
| Balaji Gandhi, Senior Vice President - Investor Relations | ||
| Mark Smith, Independent Director | ||
| Lainie Goldstein, Independent Director | ||
| Hilary Hatch, Chief Officer | ||
| Ashwin Uttamchandani, Vice Operations | ||
| Daniel Nathan, Chief Technology Officer | ||
| Kharen Hauck, Vice Marketing | ||
| Ramin Sayar, Director | ||
| Jack Callahan, Chief Officer | ||
| Maureen McKinney, Vice Communications | ||
| Allison JD, General Secretary | ||
| Thomas Altier, Chief Financial Officer | ||
| Cheryl Pegus, Independent Director | ||
| Edward Cahill, Independent Director | ||
| Janet Gunzburg, Principal VP | ||
| David Linetsky, Senior Vice President - Life Sciences | ||
| Randy Rasmussen, Chief Accounting Officer | ||
| Gillian Munson, Independent Director | ||
| Amy VanDuyn, Senior Vice President - Human Resources | ||
| Dusty Lieb, Director | ||
| Yvonne Hui, VP Officer | ||
| Allison Hoffman, General Counsel, Secretary | ||
| Michael Weintraub, Independent Chairman of the Board |
Phreesia Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Phreesia a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.4 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (0.26) % | ||||
| Operating Margin | (0.47) % | ||||
| Current Valuation | 1.15 B | ||||
| Shares Outstanding | 57.77 M | ||||
| Shares Owned By Insiders | 4.62 % | ||||
| Shares Owned By Institutions | 97.95 % | ||||
| Number Of Shares Shorted | 2.93 M | ||||
| Price To Earning | 27.08 X |
Pair Trading with Phreesia
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Phreesia position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Phreesia will appreciate offsetting losses from the drop in the long position's value.Moving against Phreesia Stock
| 0.83 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.78 | VMD | Viemed Healthcare | PairCorr |
| 0.73 | VRNA | Verona Pharma PLC | PairCorr |
| 0.73 | ETON | Eton Pharmaceuticals | PairCorr |
| 0.65 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
The ability to find closely correlated positions to Phreesia could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Phreesia when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Phreesia - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Phreesia to buy it.
The correlation of Phreesia is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Phreesia moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Phreesia moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Phreesia can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Phreesia Stock Analysis
When running Phreesia's price analysis, check to measure Phreesia's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phreesia is operating at the current time. Most of Phreesia's value examination focuses on studying past and present price action to predict the probability of Phreesia's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phreesia's price. Additionally, you may evaluate how the addition of Phreesia to your portfolios can decrease your overall portfolio volatility.